Soligenix, Inc.
- | Biotech or pharma, therapeutic R&D
Soligenix lead candidate, HyBryte™ (synthetic hypericin), for the treatment of early stage cutaneous T-cell lymphoma (CTCL) has already demonstrated positive and statistically signficant results in its first Phase 3 clinical trial and is currently enrolling in a second, confirmatory Phase 3 clincial trial, which it will look to complete in 2026.
Address
PrincetonNew Jersey
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}